Cymbalta hair loss (duloxetine) is best handled with timeline logic, because most medication-linked shedding behaves like telogen effluvium (TE): the trigger happens first, and shedding becomes noticeable later. The tricky part with duloxetine is that the FDA label history is mixed: an older U.S. Cymbalta label (2004) listed alopecia as an infrequent skin adverse reaction, while more recent U.S. Cymbalta labeling sections do not list alopecia in the skin adverse-reaction lists. That does not prove (or disprove) causation for an individual person—but it means you should rely on the highest-yield clinical clues: timing + pattern + overlap triggers.
Medical note: This article is for general education and does not provide personal medical advice. Do not stop or change Cymbalta/duloxetine without clinician guidance. If you’re not sure whether you’re seeing shedding or breakage, start here: Shedding vs Breakage. If the diagnosis is unclear, start here: How Hair Loss Is Diagnosed. If you have scalp pain/burning, pustules/crusting, heavy scale, open sores, or rapid worsening, start here: When to See a Doctor.
Quick navigation
- Key takeaways (fast)
- FDA label history: what’s documented (and what isn’t)
- Timeline: onset, peak, recovery (TE logic)
- Pattern clues: TE vs AGA vs AA vs breakage
- When labs matter (targeted workup)
- What to do (practical plan)
- When to see a doctor
- Related on this site
- References
Key takeaways (fast)
- Label history is mixed: an older U.S. Cymbalta label (2004) listed alopecia as an infrequent adverse reaction under “Skin and Subcutaneous Tissue Disorders.”
- Newer U.S. label lists skin reactions without alopecia: newer Cymbalta labeling includes skin/subcutaneous adverse-reaction lists and frequency-category definitions, but alopecia is not listed in those skin lists.
- TE timing is delayed: DermNet notes increased hair fall is noticed 2–4 months after the triggering event, and BAD notes it can occur around 3 months after a trigger.
- Don’t self-stop: if timing fits, the right move is clinician-guided risk/benefit + timeline review + alternatives if needed.
- Site context: Medication-Related Shedding • Telogen Effluvium • Blood Tests & Workup.
FDA label history: what’s documented (and what isn’t)
Documented in an older label (2004): Cymbalta labeling listed “Skin and Subcutaneous Tissue Disorders — … alopecia …” as an infrequent adverse reaction.
What newer labeling shows: newer Cymbalta labeling provides skin/subcutaneous adverse-reaction lists (and frequency-category definitions), but alopecia is not listed in those skin lists. Practically, this means you should interpret suspected cases using timing + pattern rather than assuming a single “incidence number.”
Timeline: onset, peak, recovery (TE logic)
- Onset: in TE, the key clue is delay. Increased hair fall is often noticed 2–4 months after the trigger, and it can occur around 3 months after a trigger.
- Peak: TE often feels worst for several weeks once it starts.
- Recovery: once triggers stabilize (often via clinician-guided medication strategy + correcting overlaps), shedding usually slows first; density recovery takes longer.
Pattern clues: TE vs AGA vs AA vs breakage
- Most consistent with TE: diffuse shedding, normal-looking scalp, delayed timing after starting Cymbalta or changing dose.
- TE + AGA overlap: if shedding slows but the part/crown keeps widening, consider TE unmasking pattern hair loss: TE vs Androgenetic Alopecia.
- Patchy smooth bald spots: consider alopecia areata: Alopecia Areata Hub.
- Lots of short snapped hairs: consider breakage: Hair Breakage (Hair-Shaft).
When labs matter (targeted workup)
If shedding is heavy, persistent, recurrent, or symptoms suggest overlap causes, clinicians often screen for common contributors (iron status, thyroid function, etc.). Use:
What to do (practical plan)
- Build a timeline: Cymbalta start date + dose changes + the month shedding became noticeable.
- Confirm the pattern: TE vs breakage vs overlap AGA vs AA.
- Talk to the prescriber: if timing fits, discuss options (watchful waiting vs dose adjustment vs switching) based on psychiatric risk/benefit. Do not self-stop.
- Unstack triggers: stabilize nutrition, avoid crash dieting, correct deficiencies if proven.
- Track monthly: photos every 4 weeks (same angle/light).
When to see a doctor
- Scalp pain/burning, pustules, open sores, heavy scale/crusting
- Patchy smooth bald spots
- Shedding persisting beyond ~6 months or recurrent waves
Start here: When to See a Doctor.
Related on this site
- SNRI Hair Loss: Risk, Timeline & Fixes (Overview)
- Effexor Hair Loss (Venlafaxine)
- Pristiq Hair Loss (Desvenlafaxine)
- Medication-Related Shedding
- Hair Shedding Hub
References (trusted sources)
- FDA label (2004): Cymbalta (duloxetine) — lists alopecia (infrequent)
- FDA label (2020): Cymbalta — skin adverse-reaction lists + frequency definitions
- DermNet NZ: Telogen effluvium (2–4 months after trigger)
- British Association of Dermatologists: Telogen effluvium (~3 months after trigger)
Last updated: March 08, 2026.
